

AN 2003-300573 [29] WPIX

DNC C2003-078270

TI Pharmaceutical composition e.g. for breast cancer comprises gonadotrophin releasing hormone agonist and selective estrogen receptor modulator.

DC B05

IN FURUYA, S; KUSAKA, M

PA (TAKE) TAKEDA CHEM IND LTD

CYC 100

PI WO 2003015820 A1 20030227 (200329)* JA 73<--

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU
MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO
RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

JP 2003137814 A 20030514 (200340) 25

EP 1424080 A1 20040602 (200436) EN

R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC
MK NL PT RO SE SI SK TR

AU 2002325516 A1 20030303 (200452)

ADT WO 2003015820 A1 WO 2002-JP8130 20020808; JP 2003137814 A JP 2002-231922
20020808; EP 1424080 A1 EP 2002-758814 20020808; WO 2002-JP8130 20020808;

AU 2002325516 A1 AU 2002-325516 20020808

FDT EP 1424080 A1 Based on WO 2003015820; AU 2002325516 A1 Based on WO
2003015820

PRAI JP 2001-244616 20010810

AN 2003-300573 [29] WPIX

AB WO2003015820 A UPAB: 20030505

NOVELTY - Pharmaceutical composition for breast cancer, endometriosis, myometrium tumor, Alzheimer's disease, circulatory system disorders, menopausal disorders, irregular periods, cancer metastasis, premenstrual syndrome, muscular distress or osteopathies due to calcium/phosphorus imbalance comprises a gonadotrophin releasing hormone agonist and a selective estrogen receptor modulator.

DETAILED DESCRIPTION - Pharmaceutical composition for breast cancer, endometriosis, myometrium tumor, Alzheimer's disease, circulatory system disorders, menopausal disorders, irregular periods, cancer metastasis, premenstrual syndrome, muscular distress or osteopathies due to calcium/phosphorus imbalance comprises a gonadotrophin releasing hormone agonist (GnRH) and a selective estrogen receptor modulator (SERM). INDEPENDENT CLAIMS are also included for:

- (1) the use of a GnRH and a SERM in add-back therapy;
- (2) pharmaceutical composition for prostatically or prostate cancer comprising GnRH and a selective androgen receptor modulator (SARM);
- (3) agent for treating and preventing prostatically or prostate cancer or breast cancer or their recurrence or metastasis comprising GnRH and a sex hormone synthesis inhibitor, lyase inhibitor, receptor-type tyrosine kinase inhibitor, cytokine/chemokine inhibitor or endothelin receptor antagonist;
- (4) agent for treating and preventing prostatically, breast cancer or prostate cancer or their recurrence or metastasis, menopausal disorders or osteopathies due to calcium/phosphorus imbalance comprising a GnRH and a bone metabolism regulator; and
- (5) agent for treating and preventing breast cancer or prostate cancer or their recurrence or metastasis, myometrium tumor, endometriosis or prostatically comprising a GnRH and an immunotherapy drug.

ACTIVITY - Cytostatic; Nootropic; Neuroprotective; Cardiovascular-Gen.; Endocrine-Gen.; Muscular-Gen.; Osteopathic.

No biological activity data is given.

MECHANISM OF ACTION - Gonadolibrin-Agonist; Estrogen-Agonist; Estrogen-Antagonist; Androgen-Agonist; Androgen-Antagonist; Tyrosine-Kinase-Inhibitor; Cytokine-Antagonist; Chemokine-Antagonist; Endothelin-Antagonist.